bims-minfam Biomed News
on Inflammation and metabolism in ageing and cancer
Issue of 2025–04–13
eight papers selected by
Ayesh Seneviratne, McMaster University



  1. bioRxiv. 2025 Mar 26. pii: 2025.03.24.645017. [Epub ahead of print]
      Somatic mutations that increase hematopoietic stem cell (HSC) fitness drive their expansion in clonal hematopoiesis (CH) and predispose to blood cancers. Although CH frequently occurs with aging, it rarely progresses to overt malignancy. Population variation in the growth rate and potential of mutant clones suggests the presence of genetic factors protecting against CH, but these remain largely undefined. Here, we identify a non-coding regulatory variant, rs17834140-T, that significantly protects against CH and myeloid malignancies by downregulating HSC-selective expression and function of the RNA-binding protein MSI2. By modeling variant effects and mapping MSI2 binding targets, we uncover an RNA network that maintains human HSCs and influences CH risk. Importantly, rs17834140-T is associated with slower CH expansion rates in humans, and stem cell MSI2 levels modify ASXL1-mutant HSC clonal dominance in experimental models. These findings leverage natural resilience to highlight a key role for post-transcriptional regulation in human HSCs, and offer genetic evidence supporting inhibition of MSI2 or its downstream targets as rational strategies for blood cancer prevention.
    DOI:  https://doi.org/10.1101/2025.03.24.645017
  2. Sci Immunol. 2025 Apr 11. 10(106): eadr2041
      Preserving hematopoietic stem cell (HSC) functionality is essential for maintaining healthy blood and the immune system throughout life. HSC function declines with age; however, the underlying mechanisms are not fully understood. Using an inducible mosaic mouse model to overexpress the transcription factor Bcl11a in the hematopoietic compartment, we found that an aging-related increase in Bcl11a mitigated HSC functional decline, promoted IL-1β production in the bone marrow (BM), and accelerated HSC attrition in a non-cell-autonomous manner. Aging-related inflammation in the BM enhanced Bcl11a and Fc receptor (FcR) expression in HSCs, and FcR signaling induced HSC differentiation. This was counteracted by Bcl11a through repression of Fcer1g. Bcl11a up-regulation promoted IL-1β production in BM myeloid cells, driving inflammation and HSC deterioration. Deletion of Fcer1g, or blocking IL-1β signaling, eliminated this non-cell-autonomous effect on HSC decline. These findings demonstrate that Bcl11a plays a dual role in HSCs during aging not only by cell-intrinsically preserving HSC function but also by promoting BM inflammation and HSC dysfunction.
    DOI:  https://doi.org/10.1126/sciimmunol.adr2041
  3. J Am Soc Nephrol. 2025 Apr 09.
    Chronic Renal Insufficiency Cohort (CRIC) Study Investigators
       BACKGROUND: Clonal hematopoiesis of indeterminate potential (CHIP) is a common inflammatory condition of aging that causes myriad end-organ damage. CHIP has been associated with incident AKI and kidney function decline in the general population, particularly mutations in CHIP genes other than DNMT3A (termed non-DNMT3A CHIP). Prior studies of CHIP in individuals with CKD had limited sample sizes and conflicting findings.
    METHODS: We examined CHIP and CKD progression in four CKD cohorts (N = 5,654): the Chronic Renal Insufficiency Cohort (CRIC), the African American Study of Kidney Disease (AASK), individuals with CKD from the BioVU biorepository, and the Canadian study of prediction of death, dialysis and interim cardiovascular events (CanPREDDICT).Primary outcomes were incident CKD progression (50% eGFR decline or kidney failure), and eGFR slope over time. In addition, kidney function and pathology were assessed in a Tet2-CHIP mouse model of CKD induced by dietary adenine.
    RESULTS: Across all cohorts the average age was 66 ± 11 years, with an average baseline eGFR of 43 ± 15 ml/min/1.73m2, and 24% had CHIP. After meta-analysis, non-DNMT3A CHIP was associated with a 64% higher relative risk of incident CKD progression (hazard ratio [HR] 1.64; 95% confidence interval [CI], 1.00-2.68), with the strongest effect observed in individuals with baseline eGFR 30-60 ml/min/1.73m2 (HR 1.85, 95% CI: 1.18-2.90). Non-DNMT3A CHIP carriers also exhibited a faster eGFR decline (β, -0.62 ± 0.28 ml/min/1.73m2 per year; P = 0.03). In a dietary adenine mouse model of CKD, Tet2-CHIP was associated with lower GFR as well as greater kidney inflammation, tubular injury, and tubulointerstitial fibrosis.
    CONCLUSIONS: Non-DNMT3A CHIP was associated with CKD progression among individuals with CKD. Further, Tet2-CHIP mouse models support a causal role in kidney injury.
    DOI:  https://doi.org/10.1681/ASN.0000000680